Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oramed Pharmaceuticals

2.25
-0.0400-1.75%
Volume:57.64K
Turnover:136.06K
Market Cap:91.91M
PE:-4.69
High:2.43
Open:2.40
Low:2.25
Close:2.29
Loading ...

Company Profile

Company Name:
Oramed Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
4
Office Location:
1185 Avenue of the Americas,Third Floor,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Directors

Name
Position
Nadav Kidron
President, Chief Executive Officer, Director and Chairman
Miriam Kidron
Chief Scientific Officer and Director
Arie Mayer
Director
Benjamin Shapiro
Director
Leonard Sank
Director
Yadin Rozov
Director

Shareholders

Name
Position
Nadav Kidron
President, Chief Executive Officer, Director and Chairman
David Silberman
Chief Financial Officer and Treasurer
Joshua Hexter
Chief Operating & Business Officer
Michael Rabinowitz
Chief Commercial Officer
Miriam Kidron
Chief Scientific Officer and Director
Netanel Derovan
Chief Legal Officer and Secretary